← Back to Search

Unknown

BMS-963272 for Non-alcoholic Fatty Liver Disease

Phase 1
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 166 days

Summary

This trial is testing a new drug called BMS-963272 to see if it is safe and well-tolerated in people with severe liver disease. The study focuses on those with nonalcoholic fatty liver disease (NAFLD) and a high chance of advanced fibrosis.

Eligible Conditions
  • Non-alcoholic Fatty Liver Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 166 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 166 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of clinically significant changes in electrocardiogram (ECG) parameters: PR interval
Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QRS interval
Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QT interval
+1 more

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Active Treatment (BMS-963272) Dosing Regimen 2Experimental Treatment1 Intervention
Group II: Active Treatment (BMS-963272) Dosing Regimen 1Experimental Treatment1 Intervention
Group III: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BMS-963272
2019
Completed Phase 1
~160

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,680 Previous Clinical Trials
4,125,060 Total Patients Enrolled
9 Trials studying Non-alcoholic Fatty Liver Disease
895 Patients Enrolled for Non-alcoholic Fatty Liver Disease
~2 spots leftby Oct 2025